Dobrobut Medical Network
The cost of proton therapy for prostate cancer in Ukraine typically ranges from $22,000 to $33,000. Pricing depends on the number of treatment sessions, the clinic’s technology, and the experience of the radiation oncology team. In the United States, the average cost is $100,000 (per ASTRO). This means proton therapy in Ukraine is about 73% cheaper than in the U.S.
Ukrainian clinics usually include the initial consultation, pre-treatment blood tests, personalized treatment planning, post-treatment medication, follow-up consultations, English-speaking staff, and 24/7 support. Meals during clinic visits and post-care instructions are also provided. In the U.S., costs often cover only the treatment itself, with consults, follow-ups, and support billed separately. Always confirm what’s included at your chosen clinic.
| Ukraine | Turchia | Austria | |
| Proton therapy for prostate cancer | da $22,000 | da $30,000 | da $80,000 |
Revisionato medicalmente da
Fahad MawloodBookimed non aggiunge costi extra ai prezzi di Proton therapy for prostate cancer. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica per la tua Proton therapy for prostate cancer al tuo arrivo.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali in Proton therapy for prostate cancer e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di Proton therapy for prostate cancer.
Day 1
Day 2
Day 3
Day 4 - Day 5
Day 6
Week 1 - Week 2
Week 3 - Week 4
Week 5 and onwards
Please note that each patient"s case is individual and the timeline may vary. Accommodation and transfers are not included in the therapy package and need to be arranged by the patient.
Proton therapy is a precise form of radiation therapy that targets prostate cancer tumors with minimal damage to surrounding tissues.